Report Detail
Global and Japan Neurodegenerative Drugs Market Insights, Forecast to 2026
- RnM4201580 |
- 11 September, 2020 |
- Global |
- 129 Pages |
- QYResearch |
- Pharma & Healthcare
Neurodegenerative Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Neurodegenerative Drugs market is segmented into
NMDA
SSRIs
Dopamine Inhibitors
Segment by Application, the Neurodegenerative Drugs market is segmented into
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Regional and Country-level Analysis
The Neurodegenerative Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neurodegenerative Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neurodegenerative Drugs Market Share Analysis
Neurodegenerative Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neurodegenerative Drugs business, the date to enter into the Neurodegenerative Drugs market, Neurodegenerative Drugs product introduction, recent developments, etc.
The major vendors covered:
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
1 Study Coverage
- 1.1 Neurodegenerative Drugs Product Introduction
- 1.2 Market Segments
- 1.3 Key Neurodegenerative Drugs Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global Neurodegenerative Drugs Market Size Growth Rate by Type
- 1.4.2 NMDA
- 1.4.3 SSRIs
- 1.4.4 Dopamine Inhibitors
- 1.5 Market by Application
- 1.5.1 Global Neurodegenerative Drugs Market Size Growth Rate by Application
- 1.5.2 Parkinson’s Disease
- 1.5.3 Huntington Disease
- 1.5.4 Amyotrophic Lateral Sclerosis
- 1.5.5 Alzheimer’s Disease
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Neurodegenerative Drugs Market Size, Estimates and Forecasts
- 2.1.1 Global Neurodegenerative Drugs Revenue 2015-2026
- 2.1.2 Global Neurodegenerative Drugs Sales 2015-2026
- 2.2 Global Neurodegenerative Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
- 2.3 Neurodegenerative Drugs Historical Market Size by Region (2015-2020)
- 2.3.1 Global Neurodegenerative Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.3.2 Global Neurodegenerative Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
- 2.4 Neurodegenerative Drugs Market Estimates and Projections by Region (2021-2026)
- 2.4.1 Global Neurodegenerative Drugs Sales Forecast by Region (2021-2026)
- 2.4.2 Global Neurodegenerative Drugs Revenue Forecast by Region (2021-2026)
3 Global Neurodegenerative Drugs Competitor Landscape by Players
- 3.1 Global Top Neurodegenerative Drugs Sales by Manufacturers
- 3.1.1 Global Neurodegenerative Drugs Sales by Manufacturers (2015-2020)
- 3.1.2 Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2015-2020)
- 3.2 Global Neurodegenerative Drugs Manufacturers by Revenue
- 3.2.1 Global Neurodegenerative Drugs Revenue by Manufacturers (2015-2020)
- 3.2.2 Global Neurodegenerative Drugs Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Neurodegenerative Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Neurodegenerative Drugs Revenue in 2019
- 3.2.5 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Global Neurodegenerative Drugs Price by Manufacturers
- 3.4 Global Neurodegenerative Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Neurodegenerative Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Neurodegenerative Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Neurodegenerative Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
- 4.1 Global Neurodegenerative Drugs Market Size by Type (2015-2020)
- 4.1.1 Global Neurodegenerative Drugs Sales by Type (2015-2020)
- 4.1.2 Global Neurodegenerative Drugs Revenue by Type (2015-2020)
- 4.1.3 Neurodegenerative Drugs Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global Neurodegenerative Drugs Market Size Forecast by Type (2021-2026)
- 4.2.1 Global Neurodegenerative Drugs Sales Forecast by Type (2021-2026)
- 4.2.2 Global Neurodegenerative Drugs Revenue Forecast by Type (2021-2026)
- 4.2.3 Neurodegenerative Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global Neurodegenerative Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
- 5.1 Global Neurodegenerative Drugs Market Size by Application (2015-2020)
- 5.1.1 Global Neurodegenerative Drugs Sales by Application (2015-2020)
- 5.1.2 Global Neurodegenerative Drugs Revenue by Application (2015-2020)
- 5.1.3 Neurodegenerative Drugs Price by Application (2015-2020)
- 5.2 Neurodegenerative Drugs Market Size Forecast by Application (2021-2026)
- 5.2.1 Global Neurodegenerative Drugs Sales Forecast by Application (2021-2026)
- 5.2.2 Global Neurodegenerative Drugs Revenue Forecast by Application (2021-2026)
- 5.2.3 Global Neurodegenerative Drugs Price Forecast by Application (2021-2026)
6 Japan by Players, Type and Application
- 6.1 Japan Neurodegenerative Drugs Market Size YoY Growth 2015-2026
- 6.1.1 Japan Neurodegenerative Drugs Sales YoY Growth 2015-2026
- 6.1.2 Japan Neurodegenerative Drugs Revenue YoY Growth 2015-2026
- 6.1.3 Japan Neurodegenerative Drugs Market Share in Global Market 2015-2026
- 6.2 Japan Neurodegenerative Drugs Market Size by Players (International and Local Players)
- 6.2.1 Japan Top Neurodegenerative Drugs Players by Sales (2015-2020)
- 6.2.2 Japan Top Neurodegenerative Drugs Players by Revenue (2015-2020)
- 6.3 Japan Neurodegenerative Drugs Historic Market Review by Type (2015-2020)
- 6.3.1 Japan Neurodegenerative Drugs Sales Market Share by Type (2015-2020)
- 6.3.2 Japan Neurodegenerative Drugs Revenue Market Share by Type (2015-2020)
- 6.3.3 Japan Neurodegenerative Drugs Price by Type (2015-2020)
- 6.4 Japan Neurodegenerative Drugs Market Estimates and Forecasts by Type (2021-2026)
- 6.4.1 Japan Neurodegenerative Drugs Sales Forecast by Type (2021-2026)
- 6.4.2 Japan Neurodegenerative Drugs Revenue Forecast by Type (2021-2026)
- 6.4.3 Japan Neurodegenerative Drugs Price Forecast by Type (2021-2026)
- 6.5 Japan Neurodegenerative Drugs Historic Market Review by Application (2015-2020)
- 6.5.1 Japan Neurodegenerative Drugs Sales Market Share by Application (2015-2020)
- 6.5.2 Japan Neurodegenerative Drugs Revenue Market Share by Application (2015-2020)
- 6.5.3 Japan Neurodegenerative Drugs Price by Application (2015-2020)
- 6.6 Japan Neurodegenerative Drugs Market Estimates and Forecasts by Application (2021-2026)
- 6.6.1 Japan Neurodegenerative Drugs Sales Forecast by Application (2021-2026)
- 6.6.2 Japan Neurodegenerative Drugs Revenue Forecast by Application (2021-2026)
- 6.6.3 Japan Neurodegenerative Drugs Price Forecast by Application (2021-2026)
7 North America
- 7.1 North America Neurodegenerative Drugs Market Size YoY Growth 2015-2026
- 7.2 North America Neurodegenerative Drugs Market Facts & Figures by Country
- 7.2.1 North America Neurodegenerative Drugs Sales by Country (2015-2020)
- 7.2.2 North America Neurodegenerative Drugs Revenue by Country (2015-2020)
- 7.2.3 U.S.
- 7.2.4 Canada
8 Europe
- 8.1 Europe Neurodegenerative Drugs Market Size YoY Growth 2015-2026
- 8.2 Europe Neurodegenerative Drugs Market Facts & Figures by Country
- 8.2.1 Europe Neurodegenerative Drugs Sales by Country
- 8.2.2 Europe Neurodegenerative Drugs Revenue by Country
- 8.2.3 Germany
- 8.2.4 France
- 8.2.5 U.K.
- 8.2.6 Italy
- 8.2.7 Russia
9 Asia Pacific
- 9.1 Asia Pacific Neurodegenerative Drugs Market Size YoY Growth 2015-2026
- 9.2 Asia Pacific Neurodegenerative Drugs Market Facts & Figures by Country
- 9.2.1 Asia Pacific Neurodegenerative Drugs Sales by Region (2015-2020)
- 9.2.2 Asia Pacific Neurodegenerative Drugs Revenue by Region
- 9.2.3 China
- 9.2.4 Japan
- 9.2.5 South Korea
- 9.2.6 India
- 9.2.7 Australia
- 9.2.8 Taiwan
- 9.2.9 Indonesia
- 9.2.10 Thailand
- 9.2.11 Malaysia
- 9.2.12 Philippines
- 9.2.13 Vietnam
10 Latin America
- 10.1 Latin America Neurodegenerative Drugs Market Size YoY Growth 2015-2026
- 10.2 Latin America Neurodegenerative Drugs Market Facts & Figures by Country
- 10.2.1 Latin America Neurodegenerative Drugs Sales by Country
- 10.2.2 Latin America Neurodegenerative Drugs Revenue by Country
- 10.2.3 Mexico
- 10.2.4 Brazil
- 10.2.5 Argentina
11 Middle East and Africa
- 11.1 Middle East and Africa Neurodegenerative Drugs Market Size YoY Growth 2015-2026
- 11.2 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Country
- 11.2.1 Middle East and Africa Neurodegenerative Drugs Sales by Country
- 11.2.2 Middle East and Africa Neurodegenerative Drugs Revenue by Country
- 11.2.3 Turkey
- 11.2.4 Saudi Arabia
- 11.2.5 U.A.E
12 Company Profiles
- 12.1 Novartis
- 12.1.1 Novartis Corporation Information
- 12.1.2 Novartis Description and Business Overview
- 12.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
- 12.1.4 Novartis Neurodegenerative Drugs Products Offered
- 12.1.5 Novartis Recent Development
- 12.2 Pfizer
- 12.2.1 Pfizer Corporation Information
- 12.2.2 Pfizer Description and Business Overview
- 12.2.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
- 12.2.4 Pfizer Neurodegenerative Drugs Products Offered
- 12.2.5 Pfizer Recent Development
- 12.3 Merck Serono
- 12.3.1 Merck Serono Corporation Information
- 12.3.2 Merck Serono Description and Business Overview
- 12.3.3 Merck Serono Sales, Revenue and Gross Margin (2015-2020)
- 12.3.4 Merck Serono Neurodegenerative Drugs Products Offered
- 12.3.5 Merck Serono Recent Development
- 12.4 Biogen Idec
- 12.4.1 Biogen Idec Corporation Information
- 12.4.2 Biogen Idec Description and Business Overview
- 12.4.3 Biogen Idec Sales, Revenue and Gross Margin (2015-2020)
- 12.4.4 Biogen Idec Neurodegenerative Drugs Products Offered
- 12.4.5 Biogen Idec Recent Development
- 12.5 TEVA
- 12.5.1 TEVA Corporation Information
- 12.5.2 TEVA Description and Business Overview
- 12.5.3 TEVA Sales, Revenue and Gross Margin (2015-2020)
- 12.5.4 TEVA Neurodegenerative Drugs Products Offered
- 12.5.5 TEVA Recent Development
- 12.6 UCB
- 12.6.1 UCB Corporation Information
- 12.6.2 UCB Description and Business Overview
- 12.6.3 UCB Sales, Revenue and Gross Margin (2015-2020)
- 12.6.4 UCB Neurodegenerative Drugs Products Offered
- 12.6.5 UCB Recent Development
- 12.7 Boehringer Ingelheim
- 12.7.1 Boehringer Ingelheim Corporation Information
- 12.7.2 Boehringer Ingelheim Description and Business Overview
- 12.7.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
- 12.7.4 Boehringer Ingelheim Neurodegenerative Drugs Products Offered
- 12.7.5 Boehringer Ingelheim Recent Development
- 12.8 Sanofi
- 12.8.1 Sanofi Corporation Information
- 12.8.2 Sanofi Description and Business Overview
- 12.8.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
- 12.8.4 Sanofi Neurodegenerative Drugs Products Offered
- 12.8.5 Sanofi Recent Development
- 12.9 GlaxoSmithKline
- 12.9.1 GlaxoSmithKline Corporation Information
- 12.9.2 GlaxoSmithKline Description and Business Overview
- 12.9.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
- 12.9.4 GlaxoSmithKline Neurodegenerative Drugs Products Offered
- 12.9.5 GlaxoSmithKline Recent Development
- 12.11 Novartis
- 12.11.1 Novartis Corporation Information
- 12.11.2 Novartis Description and Business Overview
- 12.11.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
- 12.11.4 Novartis Neurodegenerative Drugs Products Offered
- 12.11.5 Novartis Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter’s Five Forces Analysis
- 13.5 Primary Interviews with Key Neurodegenerative Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Neurodegenerative Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Neurodegenerative Drugs. Industry analysis & Market Report on Neurodegenerative Drugs is a syndicated market report, published as Global and Japan Neurodegenerative Drugs Market Insights, Forecast to 2026. It is complete Research Study and Industry Analysis of Neurodegenerative Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
